Keywords : hyperparathyroidism, kidney disease
Hyperparathyroidism – Analysis and Market Forecasts to 2019 Summary The global hyperparathyroidism therapeutics market is forecast to grow to reach $2.6 billion by 2019. This moderate growth is primarily attributed to the increase in the hyperparathyroidism patient population and the expected launches of two novel drugs: CTAP101 and KAI-4169 IV. The major barriers for the hyperparathyroidism therapeutics ma...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
Hyperparathyroidism – Analysis and Market Forecasts to 2019
Summary
The global hyperparathyroidism therapeutics market is forecast to grow to reach $2.6 billion by 2019. This moderate growth is primarily attributed to the increase in the hyperparathyroidism patient population and the expected launches of two novel drugs: CTAP101 and KAI-4169 IV. The major barriers for the hyperparathyroidism therapeutics market during forecast period are the introduction of bundled dialysis payment system in the US and the expected patent expirations of all three leading branded drugs in the market: Sensipar/Mimpara, Zemplar and Hectorol. The hyperparathyroidism pipeline is weak, with only seven molecules in various stages of development, including four first-in-class molecules and three me-too products. Amgen and Abbott are the leading companies in the current competitive landscape. Amgen is likely to maintain its position during the forecast period due to its acquisition in July 2012 of KAI Pharmaceuticals and its promising pipeline molecule KAI-4169.
Scope
- Overview of hyperparathyroidism, including epidemiology, etiology, symptoms, diagnosis, pathophysiology, management and treatment guidelines.
- Annualized hyperparathyroidism therapeutics market revenue, annual cost of therapy and forecast for eight years to 2019.
- Pipeline analysis: Comprehensive data split across different phases, emerging trends and mechanisms of action under development, including calcium sensing receptor agonist, vitamin D pro-hormone, vitamin D receptor agonist and CYP24 enzyme inhibitor.
- Analysis of the current and future market competition in the global hyperparathyroidism therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the hyperparathyroidism therapeutics market.
Reasons to buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global hyperparathyroidism therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global hyperparathyroidism therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global hyperparathyroidism therapeutics market from 2011–2019.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Pathology Industry in Japan
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
2.3 Upcoming Related Reports 9
3 Disease Overview 10
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 12
3.1.3 Risk Factors 13
3.1.4 Prognosis 14
3.2 Epidemiology 14
3.2.1 Prevalence 14
3.2.2 Diagnosed Prevalence 15
3.3 Symptoms 16
3.4 Diagnosis and Referral 16
3.4.1 Diagnosis 16
3.4.2 Referral 17
3.5 Treatment Guidelines 18
3.6 Disease Management 19
3.6.1 Primary Hyperparathyroidism 19
3.6.2 Secondary Hyperparathyroidism 20
3.6.3 Tertiary Hyperparathyroidism 21
4 Competitive Assessment 22
4.1 Overview 22
4.2 Strategic Competitor Assessment 22
4.3 Product Profile - Major Brands 24
4.3.1 Sensipar (cinacalcet) 24
4.3.2 Zemplar (paricalcitol) 26
4.3.3 Hectorol (doxercalciferol) 28
4.3.4 Oxarol (maxacalcitol) 29
5 Opportunity and Unmet Need 31
5.1 Overview 31
5.2 Lower Adverse Effect on Serum Calcium and Phosphorus Level 32
5.3 New Treatment Options for Primary Hyperparathyroidism 32
5.4 Disease Awareness and Screening Programs in Primary Hyperparathyroidism 32
5.5 Convenient Dosing Regimen 32
5.6 Guidelines for Tertiary Hyperparathyroidism Management 32
5.7 Pricing 33
6 Pipeline Assessment 34
6.1 Overview 34
6.2 Strategic Pipeline Assessment 34
6.3 Pipeline by Phases of Development 34
6.3.1 Phase III Pipeline 34
6.3.2 Phase II Pipeline 35
6.3.3 Phase I Pipeline 35
6.3.4 Preclinical Pipeline 35
6.3.5 Discovery Pipeline 35
6.4 Pipeline by Mechanism of Action 36
6.5 Technology Trends Analytic Framework 37
6.6 Hyperparathyroidism - Promising Drugs in Clinical Development 38
6.6.1 CTAP101 39
6.6.2 KAI-4169 IV 41
7 Clinical Trials Mapping 43
7.1 Clinical Trials by Country 43
7.2 Clinical Trials by Phase 43
7.3 Clinical Trials by Trial Status 44
7.4 Prominent Sponsors 44
8 Current and Future Players 46
8.1 Overview 46
8.2 Trends in Corporate Strategy 46
8.3 Company Profiles 47
8.3.1 Amgen Inc. 47
8.3.2 Abbott Laboratories 48
8.3.3 Cytochroma Inc. 49
8.3.4 KAI Pharmaceuticals Inc. 50
8.3.5 Other Companies in the Hyperparathyroidism Therapeutics Market 51
9 Licensing and Partnership Deals 52
9.1 Overview 52
9.2 Key Deals and Alliances in the Past 12 Months 52
10 Market Outlook 53
10.1 Seven Major Markets Overview 53
10.2 Regional Analysis 55
10.2.1 US 55
10.2.2 France 56
10.2.3 Germany 57
10.2.4 Italy 57
10.2.5 Spain 58
10.2.6 UK 58
10.2.7 Japan 59
10.3 Key Events 59
10.4 Drivers and Barriers 60
10.4.1 Drivers for the Hyperparathyroidism Market 60
10.4.2 Barriers for the Hyperparathyroidism Market 61
11 Appendix 62
11.1 Abbreviations 62
11.2 Bibliography 63
11.3 Methodology 65
11.3.1 Coverage 65
11.3.2 Secondary Research 65
11.3.3 Forecasting Methodology 66
11.3.4 Primary Research 68
11.3.5 Expert Panel Validation 69
11.4 Physicians and Specialists Included in this Study 69
11.5 About the Authors 69
11.5.1 Analysts 69
11.5.2 Global Head of Healthcare Research and Consulting 70
11.6 About GlobalData 70
11.7 Contact Us 70
11.8 Disclaimer 70
List of Tables
Table 1: Types of Hyperparathyroidism 11
Table 2: Etiology of Primary Hyperparathyroidism 11
Table 3: Etiology of Secondary Hyperparathyroidism 12
Table 4: Risk Factors for Hyperparathyroidism 13
Table 5: Prevalence of Secondary Hyperparathyroidism in Chronic Kidney Disease 14
Table 6: Total Prevalence of Hyperparathyroidism in the Major Markets, 2011-2019 15
Table 7: Diagnosed Prevalence of Hyperparathyroidism in the Major Markets, 2011-2019 15
Table 8: Symptoms of Hyperparathyroidism 16
Table 9: Diagnosis of Hyperparathyroidism 17
Table 10: Adoption of Treatment Guidelines by Physicians 18
Table 11: Treatment Guidelines for Hyperparathyroidism 18
Table 12: Surgery Criterion in Primary Hyperparathyroidism 19
Table 13: Monitoring Primary Hyperparathyroidism in Nonsurgical Patients 20
Table 14: Leading Treatments for Hyperparathyroidism, 2012 22
Table 15: Product Profile - Sensipar 24
Table 16: Adverse Incidents - Sensipar 25
Table 17: Sensipar SWOT Analysis, 2012 26
Table 18: Product Profile - Zemplar 26
Table 19: Zemplar SWOT Analysis, 2012 27
Table 20: Product Profile - Hectorol 28
Table 21: Hectorol SWOT Analysis, 2012 29
Table 22: Product Profile - Oxarol 29
Table 23: Oxarol SWOT Analysis, 2012 30
Table 24: Overall Unmet Needs - Current Level of Attainment 31
Table 25: Hyperparathyroidism - Phase III Pipeline, 2012 34
Table 26: Hyperparathyroidism - Phase II Pipeline, 2012 35
Table 27: Hyperparathyroidism - Phase I Pipeline, 2012 35
Table 28: Hyperparathyroidism - Preclinical Pipeline, 2012 35
Table 29: Hyperparathyroidism - Discovery Pipeline, 2012 35
Table 30: Comparison of Mechanisms of Actions in Development for Hyperparathyroidism, 2012 36
Table 31: Hyperparathyroidism - Promising Drugs in Clinical Development 38
Table 32: Product Profile - CTAP101 39
Table 33: CTAP101 SWOT Analysis, 2012 40
Table 34: Product Profile - KAI-4169 IV 41
Table 35: KAI-4169 IV SWOT Analysis, 2012 42
Table 36: Hyperparathyroidism Therapeutics, Clinical Trials by Phase, 2012 43
Table 37: Hyperparathyroidism Therapeutics, Clinical Trials by Status, 2012 44
Table 38: Hyperparathyroidism - Overall Sponsor Mix, 2012 44
Table 39: Key Companies in the Hyperparathyroidism Market, 2012 46
Table 40: Amgen’s Hyperparathyroidism Therapy Portfolio Assessment, 2012 47
Table 41: Amgen’s Hyperparathyroidism Therapy Portfolio SWOT Analysis, 2012 47
Table 42: Abbott’s Hyperparathyroidism Therapy Portfolio Assessment, 2012 48
Table 43: Abbott’s Hyperparathyroidism Therapy Portfolio SWOT Analysis, 2012 48
Table 44: Cytochroma’s Hyperparathyroidism Therapy Portfolio Assessment, 2012 49
Table 45: Cytochroma’s Hyperparathyroidism Therapy Portfolio SWOT Analysis, 2012 49
Table 46: KAI Pharmaceutical’s Hyperparathyroidism Therapy Portfolio Assessment, 2012 50
Table 47: KAI Pharmaceutical’s Hyperparathyroidism Therapy Portfolio SWOT Analysis, 2012 50
Table 48: Portfolio Assessment - Other Leading Players in Hyperparathyroidism Market, 2012 51
Table 49: Strategic Deals and Alliances for Hyperparathyroidism, 2012 52
Table 50: Sales Forecasts for Hyperparathyroidism in the Seven Major Markets, 2011-2019 54
Table 51: Sales Forecasts for Hyperparathyroidism in the US, 2011-2019 56
Table 52: Sales Forecasts for Hyperparathyroidism in France, 2011-2019 56
Table 53: Sales Forecasts for Hyperparathyroidism in Germany, 2011-2019 57
Table 54: Sales Forecasts for Hyperparathyroidism in Italy, 2011-2019 57
Table 55: Sales Forecasts for Hyperparathyroidism in Spain, 2011-2019 58
Table 56: Sales Forecasts for Hyperparathyroidism in the UK, 2011-2019 58
Table 57: Sales Forecasts for Hyperparathyroidism in Japan, 2011-2019 59
Table 58: Key Events Impacting Sales for Hyperparathyroidism, 2012 59
Table 59: Hyperparathyroidism Market - Drivers and Barriers, 2012 60
Table 60: Key Launch Dates 66
Table 61: Key Patent Expiries 67
List of Figures
Figure 1: Parathyroid Glands 10
Figure 2: Pathophysiology of Secondary Hyperparathyroidism 13
Figure 3: Referral and Management of Secondary Hyperparathyroidism in CKD Patients 17
Figure 4: Strategic Competitor Assessment of Marketed Products in Hyperparathyroidism, 2012 23
Figure 5: Opportunity and Clinical Unmet Need in Hyperparathyroidism, 2012 31
Figure 6: Hyperparathyroidism Therapeutics Pipeline by Phase of Clinical Development, 2012 34
Figure 7: Hyperparathyroidism - Pipeline by Mechanism of Action, 2012 36
Figure 8: Technology Trends Analytic Framework for Hyperparathyroidism Pipeline, 2012 37
Figure 9: Technology Trends Analytic Framework - Unmet Need Gap Analysis, 2012 38
Figure 10: Hyperparathyroidism Therapeutics, Clinical Trials by Country, 2012 43
Figure 11: Hyperparathyroidism - Leading Companies Participating in Clinical Trials, 2012 45
Figure 12: Sales Forecasts for Hyperparathyroidism in the Seven Major Markets, 2011-2019 54
Figure 13: Seven Major Market Sales for Hyperparathyroidism by Region, 2011-2019 55
Companies Mentioned
Amgen Inc.
Abbott Laboratories
Cytochroma Inc.
KAI Pharmaceuticals Inc.
